The Problem {#Sec1}
===========

Pregnancy culminates at the time when labour begins, implying a complex interchange of molecules generated by uterine and extrauterine tissue, leading to increased myometrial contractility, cervical dilatation, decidual/membrane activation, and rupture of chorioamniotic membranes (Romero et al. [@CR132]). The switch from a quiescent to a contractile myometrium is accompanied by a shift from anti-inflammatory to pro-inflammatory signalling chemokines and cytokines, as well as contraction-associated proteins, warranting a successful delivery (Romero et al. [@CR133]). Delivery, however, can be a risky episode, whenever the onset of pulmonary respiration is delayed or interrupted, leading to perinatal asphyxia (PA) if oxygenation is not promptly established or re-established.

PA is a relevant cause of death at the time of labour, associated with long-term consequences when re-oxygenation is established (Odd et al. [@CR111]). Despite important advances in perinatal care (Kurinczuk et al. [@CR83]; Basovich [@CR11]), PA remains a severe condition, with high prevalence (1 to 10/1000 live births) worldwide, also associated with long-lasting neuropsychiatric dysfunctions when children reach critical developmental stages (see Douglas-Escobar and Weiss [@CR34]).

PA implies a deregulation of gas exchange resulting in hypoxemia, hypercapnia, and metabolic acidosis of vital organs, including the brain (Low [@CR89]). The interruption of oxygen supply causes energy failure, triggering a biochemical cascade leading to cell dysfunction and ultimately to cell death, particularly affecting neurocircuitries of the basal ganglia and hippocampus (Klawitter et al. [@CR78]; Morales et al. [@CR103]; Neira-Peña et al. [@CR108]). The long-term effects observed after PA also imply metabolic and neuronal network alterations, impairing the ability of the CNS to cope with stressors occurring during life (see Marriott et al. [@CR95]).

Hypoxia leads to generation of reactive oxygen (ROS) and reactive nitrogen (RNS) species, inhibiting prolyl-hydroxylases that under normoxia metabolise the oxygen sensor *hypoxia-inducible factor-1alpha* (HIF-1α). This is then poly-ubiquinated by von Hippel-Lindau tumour-suppressing factor (pVHL) and eliminated by the proteasome (Wang et al. [@CR161]). Following the interruption of oxygen viability, HIF-1α accumulates and translocates to the nucleus, stimulating the expression of multiple genes associated with cell metabolism and mitochondrial function, down-regulating the citric acid cycle and enhancing anaerobic glycolysis, thus allowing the cells to cope with the low oxygen tension (Ke and Costa [@CR76]; Vangeison et al. [@CR154]). HIF-1α translocation stimulates pro-apoptotic genes, including the Bcl-2 family members Nix, Noxa, Bnip3, and apoptosis-inducing factor (AIF) (Bruick [@CR18]; Sowter et al. [@CR143]) but also the expression of sentinel proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). PARP-1 signalling occurs via the attachment of ADP-ribose chains to nuclear proteins recognised by DNA-repairing enzymes, such as DNA ligase III. The generation of ADP-ribose monomers requires, however, NAD^+^, which is why PARP-1 overactivation further depletes NAD^+^ stores, resulting in progressive ATP depletion (Berger [@CR13]; Hong et al. [@CR64]). Furthermore, there is tight crosstalk between PARP-1 and HIF-1α (Martin-Oliva et al. [@CR96]). Under hypoxic conditions and/or oxidative stress, PARP-1 modulates HIF-1α activity (Martinez-Romero et al. [@CR97]). In turn, HIF-1α requires PARP-1 activation for exerting its transcriptional activity (Pan et al. [@CR114]), while PARP-1 activity protects the HIF-2α isoform against pVHL-mediated destabilization (Gonzalez-Flores et al. [@CR49]).

Hypoxia implies a generalised impairment of Na^+^/K^+^-ATPase-dependent transport, including neurotransmitter re-uptake. A particular case is that of glutamate, which is largely synthesised by the astroglia-neuronal glutamine shuttle. It is not yet clear how ATPase modulates glutamate transport. However, arachidonic acid inhibits several sodium-coupled amino acid transporters, including that of glutamate, by a mechanism requiring Na^+^/K^+^-ATPase (Danbolt [@CR30]). Furthermore, there is evidence showing that extracellular glutamate levels are buffered by ATP-dependent transport, to be taken up by glial and neuronal cells for metabolic degradation or re-cycling (Herrera-Marschitz et al. [@CR58]). ATP deficit decreases glutamate uptake, resulting in increased extracellular glutamate levels. Free radicals can also affect the members of the Na^+^/Cl^−^-dependent transporter family, although the role of oxidative modulation of glutamate uptake under normal conditions is not yet known, and even less under hypoxia (Danbolt [@CR30]). It has been shown, however, that glutamate transporters possess a sulfhydryl-based regulatory mechanism, which makes glutamate transporters sensitive to redox agents, resulting in increased or decreased transport (Trotti et al. [@CR153]). It is hypothesised here that under sustained hypoxia the half-life of extracellular glutamate is prolonged. This might provide an extreme homeostatic response for widespread neuronal depolarization removing the organism from a catastrophic condition by extracellular glutamate binding to any available glutamate receptor, mainly of the extrasynaptic subtype. The NMDARs are heterotetramers composed by two NR1 (obligatory) and two NR2/3 subunits (Jacobucci and Popescu [@CR70]), whose gating and ligand-binding properties depend on the NR2A/C subunit (Glasow et al. [@CR47]). The NR2B-containing NMDARs are extrasynaptic in a significant proportion (Papouin et al. [@CR115]). At birth, extrasynaptic NR2B-containing receptors prevail over the NR2A-containing NMDAR subtype. The NR2A-containing subtype is the predominant intrasynaptic mature NMDAR, associated with long-term plasticity (see Petralia [@CR119]; Vizi et al. [@CR159]). The NR2B subtype is associated with excitotoxic cascades and cell death, via Ca^2+^ cellular entry and massive mitochondrial Ca^2+^ loading (Loftis and Janosky [@CR87]; Stanika et al. [@CR144]). Thus, sustained hypoxia necessarily implies excitotoxicity, worsening in turn the metabolic crisis and death if respiration is not promptly established.

Overstimulation of extrasynaptic NMDA receptors increases nitric oxide (NO) production, and further oxidative stress by formation of peroxynitrite upon its reaction with superoxide anions. NO can directly decrease mitochondrial membrane potentials, liberating pro-apoptotic proteins (Moncada and Bolaños [@CR101]), including AIF, NADPH oxidase, and neuronal nitric oxide synthase (nNOS) (Hwang et al. [@CR65]), provoking DNA fragmentation and mitochondrial fission, maintaining a condition of high ADP/ATP ratio and energy inefficiency (Pérez-Pinzon et al. [@CR117]). Mitochondrial structure, function, and energy metabolism change over time, implicating that the physiology of mitochondria also evolves along the life span of an individual (Mattson [@CR99]).

Upon delivery and during neonatal and early developmental stages, oxidative stress is a permanent risk for the developing individual, enhanced by a sudden increase or decrease of metabolism associated with development itself or environment-dependent conditions, including malnutrition, fatigue, fever, infections, trauma, and/or inflammation-inducing injuries (Deng [@CR33]). Oxidative stress produces an imbalance that favours the production of ROS over antioxidant defences (Orrenius et al. [@CR113]), with hydrogen peroxide (H~2~O~2~) playing a pivotal role (Sies [@CR141]). At low concentrations (1--10 nM), H~2~O~2~ leads to adaptative stress responses, while above 1 μM H~2~O~2~ induces inflammation, growth arrest, and cell death (Deng [@CR33]; Aschbacher et al. [@CR9]).

An Experimental Model of Global PA in Rats {#Sec2}
==========================================

In our laboratory, we established an experimental model of global PA in rats, originally proposed by Borje Bjelke, Kurt Andersson, and collaborators at the Karolinska Institutet, Stockholm, Sweden, in the 1990s (Bjelke et al. [@CR15]; Andersson et al. [@CR7]; Herrera-Marschitz et al. [@CR56]). In this model, hypoxia occurs at the time when the rats are ready for or have begun delivery. The model has been pivotal for the study of relevant targets responsible for metabolic cascades leading to long-term effects (see Herrera-Marschitz et al. [@CR62], [@CR63]; recently reviewed by Barkhuizen et al. [@CR10]).

The model starts by a programmed mating. At the time of pro-oestrus, a female Wistar rat is exposed to a male for one night, looking the next day for a vaginal clot to exactly predict the time of delivery (22 days). When on term, a first spontaneous delivery is observed before the dam is neck-dislocated and subjected to hysterectomy to remove the foetus-containing uterine horns, which are immersed in a water bath at 37 °C for 21 min in order to induce severe asphyxia. The foetuses are manually delivered and stimulated to start breathing, and after a nursering period, the pups are given to surrogate dams pending further experiments. Sibling, spontaneous, or caesarean-delivered pups are used as controls (see Herrera-Marschitz et al. [@CR62]). The model allows monitoring early or delayed long-lasting molecular, metabolic, and physiological effects, or the pups can also be used to prepare organotypic cultures (Morales et al. [@CR102]; Klawitter et al. [@CR78]).

PA is a menace to the full organism, affecting systemic and brain tissue. The availability of ATP is rapidly decreased in the kidneys, already after 5 min of PA, whereas brain ATP is decreased to less than 50% after 15 min of asphyxia if performed at 37 °C (Engidawork et al. [@CR37]). Heart metabolism is sustained until the time when the lack of oxygenation is incompatible with life, largely supported by the "phosphocreatine shuttle" (Friedman and Roberts [@CR42]), which is not useful for the neonatal brain (Lubec et al. [@CR92]), although there is some clinical evidence showing that a creatine-supplemented diet protects the newborn from birth hypoxia (Ireland et al. [@CR67], [@CR68]; Tachikawa et al. [@CR146]), but further research is certainly required to evaluate the phosphocreatine shuttle in the developing brain.

PA implies a primary and a secondary insult. The primary insult relates to the lack of oxygen, and the secondary one to the oxidative stress triggered by re-oxygenation, resulting in the formation of ROS and RNS, and overactivation of glutamate receptors and mitochondrial deficiencies, as recently discussed (Hagberg et al. [@CR52]).

The Hypoxic Insult {#Sec3}
==================

The brain is vulnerable to a decrease of blood oxygen saturation, due to its high dependence on aerobic metabolism. Whenever hypoxia is sustained, there is a switch to glycolysis, a poor metabolic alternative because of the low glucose stores in newborn brain tissue and deficient ATP output by the glycolysis pathway, resulting in lactate accumulation and acidosis (Engidawork et al. [@CR37]). The cerebral energy metabolism of newborn rodents and humans can utilise ketone bodies β-hydroxybutyrate and acetoacetate rather than glucose to satisfy cerebral energy requirements (see Nehlig and Pereira de Vasconcelos, [@CR109]). In neonates, these ketone bodies are essential energy sources, produced by liver mitochondria and diffusing to other organs including the brain. Ketone uptake into the brain of the newborn is four to five times faster than that in older babies or infants (Cunnane and Crawford [@CR29]). In adults, ketones can provide the energy requirements following prolonged fasting or starvation (Wang et al. [@CR162]), and are also the main source of carbon to make cholesterol and long-chain fatty acids, important structural lipids for the developing brain (Cunnane et al. [@CR28]). It is not yet known, however, if ketone bodies can compensate for the energy crisis elicited by hypoxia during the perinatal period.

The Re-oxygenation Insult {#Sec4}
=========================

Re-oxygenation is a requirement for survival, leading necessarily to oxidative stress and free radical formation, excitotoxicity, intracellular calcium accumulation, mitochondrial dysfunction, and inactivation of buffering enzymes, resulting in a metabolic deficient condition, increasing CNS vulnerability to recurrent metabolic insults.

Oxidative stress and free radical formation lead to inhibition of Na^+^-dependent glutamate uptake by astroglial cells, the main mechanism regulating extracellular glutamate levels (Herrera-Marschitz et al. [@CR58]; see Anderson and Swanson [@CR6]) implicated in short- and long-term excitoxicity, as discussed by Herrera-Marschitz and Schmidt ([@CR59]). The impairment of glial-glutamate transport leads to extracellular glutamate overflow. If not taken up, glutamate binds to extrasynaptic NMDARs, expressing at neonatal stage Ca^2+^-permeable NR2B and Mg^2+^-insensitive NR3A NMDAR subunits (Massey et al. [@CR98]; see Groc et al. [@CR50]; Hardingham and Bading [@CR54]; Jantzie et al. [@CR72]; also, Papouin et al. [@CR115]). Overstimulation of extrasynaptic NMDAR increases Ca^2+^ influx, triggering mitochondrial dysfunction and ROS and RNS formation (Starkov et al. [@CR145]; Stanika et al. [@CR144]), modifying lipids and macromolecules, such as proteins and nucleic acids (see Quincozes-Santos et al. [@CR127]). There is evidence that NMDA receptor blockage improves mitochondrial respiration, preventing mitochondrial permeabilization during the reperfusion phase following hypoxic-ischaemic injury (Block and Schwarz [@CR16]; Chen et al. [@CR24]; Puka-Sundvall et al. [@CR126]).

ROS and RNS levels can overwhelm the capacity of cellular defence systems. ROS introduce post-translational oxidative carbonyl modifications on macromolecules (Lourenco dos Santos et al. [@CR88]), while S-nitrosylation modifies reactive cysteine thiol on target proteins, leading to both protein misfolding and fission/fusion-dependent mitochondrial dysfunction and fragmentation (Nakamura and Lipton [@CR105]). PARP-1 is further activated (Duan et al. [@CR35]; Abramov and Duchen [@CR1]), and AIF is translocated, triggering caspase-independent apoptosis (see Krantic et al. [@CR81]). ROS alter IκB degradation, resulting in NF-κB activation, and nuclear translocation of the p65 subunit, which is increased in a PARP-1-dependent manner by PA (Neira-Peña et al. [@CR108]). The global perinatal insults trigger inflammatory signalling in peripheral and brain tissues, implicating also vascular integrity. Cyclooxygenase-2 (COX-2), a marker of inflammation, is transiently elevated in rat brain exposed to PA, together with up- and subsequent down-regulation of antioxidant enzymes (Toti et al. [@CR151]; Bonestroo et al. [@CR17]). This suggests delayed vulnerability that could contribute to developmental abnormalities responsible for the behavioural alterations observed after PA (Piscopo et al. [@CR122]), also in the ischaemic neonatal human brain (Toti et al. [@CR151]). At neonatal stages, the effect of increased ROS and RNS is aggravated by immature defence mechanisms, including low expression/activity of the superoxide dismutase (SOD) family, glutathione peroxidase (GPx) (Samarasinghe et al. [@CR137]), catalase (Lafemina et al. [@CR84]), and peroxyredoxin-3 (Prx-3) (Chang et al. [@CR22]). Prx-3 is exclusively located in mitochondria, co-localising with SOD-2 (Mn-SOD) (Watabe et al. [@CR166]; Cao et al. [@CR21]). Prx-3 protects against peroxynitrite anions (Hattori et al. [@CR55]; see Hanschmann et al. [@CR53]), and it is expressed heterogeneously, correlating with a regional sensitivity to excitotoxic damage (Hattori et al. [@CR55]; Aon-Bertolino et al. [@CR8]).

Current Brain-Protecting Strategies {#Sec5}
===================================

Therapeutic options against the long-term effects of PA are limited and mainly based on hypothermia, which provides protection only if initiated soon after the insult (Thoresen et al. [@CR150]). No consensus on clinical protocols has been achieved yet, and the advantages and disadvantages of head or whole body cooling are still debated, including safety and developmental considerations (Committee on Fetus & Newborn [@CR27]; Allen [@CR4]; Shankaran et al. [@CR140]; Sabir and Cowan [@CR135]; Ahearne et al. [@CR2]).

Hypothermia {#Sec6}
===========

There is compelling clinical evidence that cerebral hypothermia improves the neurodevelopmental outcome when applied to infants with moderate to severe hypoxic-ischaemic encephalopathy (HIE), before the onset of a secondary deterioration phase (Edwards et al. [@CR36]; Guillet et al. [@CR58]; Shankaran et al. [@CR139]; see Wassink et al. [@CR165]; Vanlandingham et al. [@CR155]). This has led to a recommendation supported by the *European Resuscitation Council* that any new therapeutic approach dealing with neonatal encephalopathy should be compared to the effect produced by hypothermia (Davidson et al. [@CR32]; Gunn and Thoresen [@CR51]).

As mentioned above, the current hypothermia protocols are still insufficient (Allen [@CR4]), and a main drawback is the existence of a narrow therapeutic window (Odd et al. [@CR111]; Sabir and Cowan [@CR135]; Ahearne et al. [@CR2]). The rationale of hypothermia is graded reduction of cerebral metabolism, about 5% for every degree Celsius of temperature reduction (Laptook et al. [@CR85]; Erecinska et al. [@CR39]). Cooling also reduces post-depolarization release of excitatory amino acids during hypoxia-ischaemia, both in newborn (Thoresen et al. [@CR149]) and in adult (Nakashima and Todd [@CR107]) subjects. Microdialysis experiments showed that hypothermia initiated immediately after hypoxia-ischaemia in newborn piglets was associated with reduced levels of excitatory amino acids and reduced NO efflux compared to the control condition (Thoresen et al. [@CR149]; Rostami et al. [@CR134]), in agreement with evidence that glutamate antagonists can also prevent events occurring in the early recovery phase following hypoxia-ischaemia, before failure of mitochondrial function takes place, but only when the effect of the antagonist is associated with hypothermia (Nurse and Cobertt [@CR110]).

PARP-1 Overactivation {#Sec7}
=====================

PARP-1 plays a critical role during development, and is activated upon any threat to the genome, either for its repair or for initiating cell death signalling to protect its integrity. Indeed, PARP-1 overactivation elicits a NMDAR-dependent, caspase-independent, parthanatos-like cell death programme (Wang et al. [@CR164]) and PA increases PARP-1 activity in the rat brain shortly after the insult (Allende-Castro et al. [@CR5]), triggering a signalling cascade leading to nuclear translocation of the NF-κB subunit p65 and the expression of the pro-inflammatory proteins IL-1β and TNF-α, increasing cell death (Neira-Peña et al. [@CR108]). Such effects are prevented by the PARP-1 inhibitor nicotinamide, supporting previous reports showing similar protection against neuronal death (Klawitter et al. [@CR78]), brain dopaminergic dysfunction (Bustamante et al. [@CR20]), and behavioural deficits (Simola et al. [@CR142]; Morales et al. [@CR104]) assessed 2--6 months after the perinatal insult. PARP-1 inhibition attenuates nNOS activation and reduces cell death induced by oxidative conditions (Pieper et al. [@CR120]; Klawitter et al. [@CR78]), restoring metabolic functions including energy production (Chen et al. [@CR25]; Xu et al. [@CR169]). Nicotinamide, as an NAD^+^ precursor, probably protects against the metabolic cascade elicited by the primary insult, avoiding NAD^+^ exhaustion and the energy crisis.

While the hypothesis of PARP-1 inhibition is promising, it has yet to reach a consensus in order to attempt a clinical trial, in part because nicotinamide does not provide full protection against the effects elicited by PA. Nicotinamide prevents vulnerability to recurrent metabolic insults, but mainly in the substantia nigra, with only minor effects in the neocortex and neostriatum (Neira-Peña et al. [@CR108]; Perez-Lobos et al. [@CR116]). The issue of analogues, precursors, or metabolites of nicotinamide is attractive (Trammell et al. [@CR152]), recently discussed in relation to nicotinamide riboside, which improves mitochondrial and stem cell function, prolonging the life span of mice (Zhang et al. [@CR170]).

Nicotinamide mononucleotide has been shown to be superior to nicotinamide as a precursor of NAD^+^ (Kawamura et al. [@CR75]), leading to the proposal that nicotinamide mononucleotide protects from energy deficits by restoring NAD^+^ and ATP levels, reducing ROS accumulation (Wang et al. [@CR164]). The oral bioavailability of nicotinamide mononucleotide has been reported, and this intermediate mitigates age-associated physiological decline in mice without any obvious toxicity or deleterious effects, enhancing mitochondrial oxidative metabolism and preventing mitonuclear protein imbalance (Mills et al. [@CR100]). It is not yet known whether nicotinamide riboside or mononucleotide can also decrease PARP-1 overactivation, or whether they can prevent the long-term consequences of PA.

Glutamate Excitotoxicity {#Sec8}
========================

The involvement of glutamate in excitotoxicity-mediated damage induced by metabolic insults, including stroke, ischaemia, and hypoxia, led to the strategy of treating with selective high-affinity NMDA and/or AMPA antagonists, all of which failed in clinical trials (Cheng et al. [@CR26]). The classical non-competitive NMDAR antagonist dizocilpine (MK-801) gave hope for death prevention following PA (Herrera-Marschitz et al. [@CR56], [@CR57]; Engidawork et al. [@CR38]), but it was largely surpassed by hypothermia. It was also discussed whether the minor protection provided by MK-801 is explained by a hypothermia-induced effect (Buchan and Pulsinelli [@CR19]; see Alkan et al. [@CR3]; Makarewicz et al. [@CR93]).

Several glutamate transporter proteins are expressed by astrocytes, mainly GLAST (EAAT1) and GLT-1 (EAAT2) subtypes, responsible for the majority of glutamate uptake (see Robinson and Jackson [@CR131]), providing a target for increasing or decreasing extracellular glutamate levels (Herrera-Marschitz et al. [@CR58]). *N*-Acetylcysteine, a clinically established antioxidant, has been shown to activate the cystine/glutamate antiporter, modulating extracellular glutamate levels (Danbolt [@CR30]; see Berk et al. [@CR14]). The actual direction of the transport of cystine or glutamate depends upon the intracellular and extracellular concentration of the respective molecules. Several clinical studies have shown that *N*-acetylcysteine is well tolerated, promising a role for the treatment of a number of neuropsychiatric disorders (Wink et al. [@CR167]; see Berk et al. [@CR14]). In the brain, *N*-acetylcysteine is deacetylated and oxidised to cystine, which is reduced back to cysteine when taken up by the cells, playing a role in the synthesis of glutathione (GSH) (Bavarsad Shahripour et al. [@CR12]). Thus, *N*-acetylcysteine is perhaps an option to be tested in the present model (see Quintanilla et al. [@CR128]).

Memantine as a Lead for a Neonatal Protecting Strategy {#Sec9}
======================================================

D145 (1-amino-3,5-dimethyladamantane), better known as memantine, was first proposed as a putative anti-parkinsonian drug in the 1980s, since it induced rotational behaviour in unilaterally 6-OHDA-lesioned animals with a profile mimicking that of [d]{.smallcaps}-amphetamine and apomorphine, indirect and direct dopamine agonists respectively (Danysz et al. [@CR31]; see Herrera-Marschitz et al. [@CR60], [@CR61]). This was confirmed by Seeman et al. ([@CR138]), demonstrating the action of memantine on dopamine D~2~ receptors. Nevertheless, the main pharmacodynamic feature supporting a clinical application in stroke, ischaemia, or neurodegenerative disorders was based on the observation that memantine is a low-affinity, use-dependent, NMDAR channel blocker with fast kinetics, not interfering with normal synaptic transmission, but blocking NMDAR only when it is overstimulated (Volbracht et al. [@CR160]; Rammes et al. [@CR129]). Memantine is considered at present as a prototype for targeting extrasynaptic NMDR activity (Garcia-Munoz et al. [@CR45]; Johnson et al. [@CR73]).

Memantine is well tolerated and has a low incidence of adverse effects (Kavirajan [@CR74]), also inducing mild hypothermia (Krieglstein et al. [@CR82]), a feature further supporting its clinical potential (see Rammes et al. [@CR129]). Memantine has been approved by the European Medicine Agency and the Food and Drug Administration (FDA-USA) for the treatment of moderately severe Alzheimer's disease (2006). It has been reported that memantine can reduce functional and morphological sequelae induced by ischaemia (Block and Schwarz [@CR16]; Chen et al. [@CR24]; Volbracht et al. [@CR160]), possibly by selectively blocking extrasynaptic NMDAR (Chen et al. [@CR23]; Xia et al. [@CR168]; Garcia-Munoz et al. [@CR45]). Memantine has also been evaluated for efficacy in children with pervasive developmental disorders, including leukomalacia, while there is still concern about increasing constitutive apoptosis, recommending further preclinical investigation (Manning et al. [@CR94]).

An important issue refers to whether memantine prevents the excitotoxic cascade elicited by PA. This question merits investigation, either with memantine alone and/or together with the PARP-1 inhibitor nicotinamide, to assess prevention of the short- and long-term effects elicited by PA, profiting also from the mild hypothermia induced by memantine (Krieglstein et al. [@CR82]; Gunn and Thoresen [@CR51]). Memantine can improve mitochondrial respiration, preventing mitochondrial permeabilization during the secondary (reperfusion) phase following hypoxic-ischaemic injury (Block and Schwarz [@CR16]; Chen et al. [@CR24]; Pirinen et al. [@CR121]; Olah et al. [@CR112]), in agreement with a pivotal role of extrasynaptic NMDA receptors in the effects elicited during the re-oxygenation phase following hypoxia.

The chemical structure of memantine (3,5-dimethyltricyclo\[3.3.1.1^3,7^\]decan-1-amine) allows additional groups to be attached to increase selectivity, improving its pharmacodynamic and/or pharmacokinetic properties. Hence, nitromemantine has been synthesised, by attaching a nitrate group to produce 3-amino-5,7-diethyladamantan-1-yl nitrate. This NO source improved efficacy as a neuroprotectant, compared to that provided by memantine, by nitrosating a redox-mediated regulatory site on the extrasynaptic NMDA receptor (Lipton [@CR86]; Takahashi et al. [@CR147]; see Nakamura and Lipton [@CR106]).

Hypothermia and excitatory amino acid blockage can provide a potent synergism for prevention of the secondary energetic mitochondrial-related failure associated with PA. Nevertheless, many of the compounds used for blocking the initial phases of injury, excitotoxicity, and oxidative stress elicited by hypoxic-ischaemic encephalopathy failed, also because of blockage of normal functions associated to glutamatergic signalling. MK-801 decreases death following PA (Peruche and Krieglstein [@CR118]; Herrera-Marschitz et al. [@CR56], [@CR57]), but it also induces apoptosis, impairing brain development in rats (Ikonomidou et al. [@CR66]).

Vulnerability to Recurrent Metabolic Insults {#Sec10}
============================================

Neonatal metabolic insults may lead to immediate and/or delayed consequences, with clinical onset at different developmental stages. Understanding the sequence of these events is still sketchy. Nevertheless, it has been discussed that metabolic insults occurring at birth (a first hit) can prime development, increasing the vulnerability to recurrent (secondary and tertiary hit) insults, ultimately challenging postnatal development and maturity. In humans, PA is a risk factor for several psychiatric disorders, including learning deficits and schizophrenia. Conversely, in rodents, PA is associated with delayed cell death, dopamine and histamine transmission deficits and behavioural impairments assessed at adulthood, affecting learning, spatial, and non-spatial memory and anxiety (Simola et al. [@CR142]; Morales et al. [@CR104]; Galeano et al. [@CR43], [@CR44]; Flores-Balter et al. [@CR41]; Tapia-Bustos et al. [@CR148]). The idea of progressive dysfunction and "first" and successive hit sequences, triggering and perpetuating pathophysiological conditions and/or diseases, has recently been discussed (Marriott et al. [@CR95]; Israel et al. [@CR69]). In agreement with this, it was recently reported that PA implies a long-term energy deficit and oxidative stress, evaluated by the ADP/ATP and GSH/GSSG ratio, respectively, prevented by nicotinamide (Perez-Lobos et al. [@CR116]). Figure [1](#Fig1){ref-type="fig"} shows the effect of PA and a recurrent metabolic insult (1 mM H~2~O~2~) on ADP/ATP (Fig. [1](#Fig1){ref-type="fig"}a), GSH/GSSG (Fig. [1](#Fig1){ref-type="fig"}b), and potassium ferricyanide-reducing power (Fig. [1](#Fig1){ref-type="fig"}c) measurements on entire sample homogenates from triple organotypic cultures from caesarean-delivered and asphyxia-exposed rat neonates, making it evident that PA produces a permanent energy deficit (increased ADP/ATP ratio) and oxidative stress (decreased GSH/GSSG ratio), as well as a permanent deficit in reducing antioxidant power, increasing vulnerability to recurrent insults (Perez-Lobos et al. [@CR116])Fig. 1ADP/ATP (**a**), GSH/GSSG (**b**), and )**c**) potassium ferricyanide-reducing power measurements on entire sample homogenates from triple organotypic cultures. **a** ADP/ATP ratio observed in cultures at 21 days in vitro (DIV) from caesarean-delivered (controls; CS) (*open columns*) and asphyxia-exposed (AS) (hatched columns) rat neonates (P2) (means ± SEM; *n* = 6, for each experimental groups). **b** GSH/GSSG ratio. **c** Potassium ferricyanide-reducing power. ^a^ *P* \< 0.05 for the effect of asphyxia (CS + Sal versus AS + Sal); ^b^ *P* \< 0.05 for the effect of H~2~O~2~ (CS + Sal + 0 mM H~2~O~2~ versus CS + Sal + 1 mM H~2~O~2~, or AS + Sal + 0 mM H~2~O~2~ versus AS + Sal + 1 mM H~2~O~2~). ^c^ *P* \< 0.05, for the effect of nicotinamide (NAM) (CS + Sal + 0 mM H~2~O~2~ versus CS + NAM + 0 mM H~2~O~2~; CS + Sal + 1 mM H~2~O~2~ versus CS + NAM + 1 mM H~2~O~2~; AS + Sal + 0 mM H~2~O~2~ versus AS + NAM + 0 mM H~2~O~2~; AS + Sal + 1 mM H~2~O~2~ versus AS + NAM + 1 mM H~2~O~2~) (data from Perez-Lobos et al. [@CR116])

Conclusions {#Sec11}
===========

The present review focuses on the short- and long-term metabolic cascades triggered by PA, identifying pathways that can explain long-term vulnerability and clinical consequences. The Karolinska Institutet model of PA has recently been discussed by a review summarising 25 years of research on global asphyxia in the immature rat brain (Barkhuizen et al. [@CR10]).

PA is still a prominent clinical issue with few therapeutic alternatives preventing its long-term consequences. We have established a unique experimental model of global PA in rats occurring at the time of delivery, identifying relevant targets responsible for metabolic cascades leading to short- and long-term effects, evaluated by in vivo and in vitro experiments (see Herrera-Marschitz et al. [@CR62], [@CR63]). The model is a referent among those used for studying progressive neurological dysfunction originating early in life (Marriot et al. [@CR95]). PA constitutes a model of neural damage and regeneration for many other conditions such as stroke, where hypoxia/ischaemia is often followed by re-oxygenation and injury.

The discussed model has been compared to that of hypoxia/ischaemia proposed by Rice et al. ([@CR130]) (Vannucci and Vannucci [@CR156]; Vannucci et al. [@CR157], [@CR158]), marshalling the fact that the reviewed model is performed with on-term and not with neonates at P7, the former being premature when compared to the neonatal human brain. The prematurity of the neonatal rat brain has been a subject of controversy, arguing that the degree of maturity depends upon the tissue and the functions selected for comparison (Herrera-Marschitz et al. [@CR63]). Further, the model of Vannucci and collaborators involves ligation of vessels, resulting in a pathophysiology equivalent to focal stroke, not necessarily triggered by global asphyxia (Fellman and Raivio [@CR40]). The here discussed model (i) is a good mimic of human delivery (Romero et al. [@CR132]); (ii) it is largely non-invasive, not involving vessel ligation, ischaemia, or exposure of pulmonary breathing animals to N~2~ inhalation chambers (Fellman and Raivio [@CR40]); (iii) it allows evaluation of short- and long-term consequences of the insult, monitored in the same preparation (Kohlhauser et al. [@CR80], [@CR79]; Simola et al. [@CR142]; Morales et al. [@CR104]); (iv) it is highly reproducible among laboratories (Lubec et al. [@CR91], [@CR90]); and (v) it is considered as a reference by worldwide leading labs (see Wassink et al. [@CR165]; Gunn and Thoresen [@CR51]). Furthermore, (vi) the model is unique in providing a bridge between in vivo and in vitro experiments, based on the same preparation. Indeed, foetuses and neonates can be used to prepare organotypic cultures, complementing and/or allowing experiments with bioethical restrictions when performed in vivo, such as exposing surviving neonates to a recurrent insult (Perez-Lobos et al. [@CR116]).

The organotypic culture model originally developed by BH Gahwiler in Zurich ([@CR46]) was validated by Plenz and Kitai ([@CR123], [@CR124]; Plenz et al. [@CR125]), as a powerful tool for studying rat basal ganglia neurocircuitries. In this model, the pattern of neuronal innervation and neurocircuitry formation is moved back to an earlier stage, providing an opportunity to monitor under the microscope how neurites and processes look for their corresponding targets, establishing innervation plexuses, showing electrophysiological (Plenz and Kitai [@CR124]) and neurochemical (Gomez-Urquijo et al. [@CR48]) features similar to those observed in vivo. The model has been used to demonstrate the effect of PA on the number and branching of tyrosine-hydroxylase-positive neurons, illustrating the vulnerability of the dopaminergic systems to PA (Morales et al. [@CR102]; Klawitter et al. [@CR77], [@CR78]). We have recently reported that the organotypic model allows evaluation of the effect of PA on postnatal vulnerability to oxidative stress, demonstrating an additive effect to that produced by PA on cells with neuronal and glial phenotype, prevented by systemic nicotinamide treatment 1 h after birth (Perez-Lobos et al. [@CR116]).

PA provides a framework to address a fundamental issue affecting long-term CNS plasticity. The perinatal insult triggers a domino-like sequence of events making the developing individual vulnerable to recurrent adverse conditions, decreasing his/her coping repertoire because of a relevant insult occurring at birth (Marriott et al. [@CR95]). The issue of the short- and long-term consequences of PA has heuristic relevance, since PA implicates a long-term biological vulnerability that fully depends on the severity of an insult occurring at birth, independently of any genetic or clinical predisposition (Sahin and Sur [@CR136]; Jain et al. [@CR71]). Indeed, by definition, PA (an environmentally dependent variable) refers to an unexpected interruption of oxygen at the time of delivery, when labour has already begun. Therefore, no genetic factor, malformation, or prematurity is included in the clinical entity of PA, which is defined as a specific metabolic/energetic insult related, first, to the delay and/or interruption of autonomous breathing, and, second, to re-oxygenation, a requirement for survival.
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